Genetic mutations in pancreatic ductal adenocarcinoma (PDAC) with critical roles have been well examined. The recent discovery of alterations in genes encoding histone modifiers suggests their possible roles in the complexity of cancer development. We previously reported loss of heterozygosity of the KDM6B gene, which encodes a histone demethylase for trimethylated histone H3 lysine 27, a repressive chromatin mark, in PDAC cells. In this study, we demonstrated that loss of KDM6B enhanced aggressiveness of PDAC cells. KDM6B has been regarded as a tumor suppressor that mediates oncogenic KRAS-induced senescence. Consistently, KDM6B was highly expressed in pancreatic precancerous lesions (pancreatic intraepithelial neoplasms); then, the expression decreased as the malignant grade progressed. We found that knockdown of KDM6B in PDAC cells promoted tumor sphere formation and increased peritoneal dissemination and liver metastasis in vivo. Microarray and chromatin immunoprecipitation analysis implicated CEBPA for aggressiveness induced by KDM6B knockdown. CEBPA knockdown recapitulated the phenotypic change of PDAC cells after KDM6B knockdown, which was reversed by forced expression of C/EBPα. Moreover, similar protein expression patterns of KDM6B and C/EBPα in human PDAC emphasized their functional correlation. Notably, pharmacological inhibition of the H3K27 methylase EZH2 in PDAC cells inhibited tumor sphere formation along with the upregulation of CEBPA expression, and this effect was impaired in KDM6B knockdown cells, highlighting the role for KDM6B in the activation of CEBPA. Together, our results propose a significant role for the KDM6B-C/EBPα axis in the PDAC phenotype.
Introduction
Pancreatic cancer is the fourth and fifth leading cause of cancerrelated death in the USA and Japan, respectively (1), with pancreatic ductal adenocarcinoma (PDAC) representing the most common histological subtype. The vast majority of PDAC harbors oncogenic mutations in KRAS and inactivated CDKN2A/p16, SMAD4 and TP53 tumor suppressor genes (2, 3) . Notably, these mutations are already present in pancreatic intraepithelial neoplasms (PanINs), the most common precursor lesions to PDAC (4) , and their prevalence gradually increases during neoplastic progression. Moreover, genetically engineered mice harboring oncogenic KRAS mutations in the pancreas spontaneously develop PanINs (5) , and additional inactivation of CKDN2A/p16, SMAD4 and TP53 accelerates PDAC formation in these mice (6) (7) (8) , verifying the critical roles of these genetic changes in the development and progression of PDAC. Nonetheless, as has been described previously (9) , the degree of cytological and architectural atypia in a pancreatic lesion does not always correlate with these genetic changes, raising the possibility that unidentified genetic alterations or epigenetic factors might also be involved in the progression of pancreatic neoplasia.
Epigenetic changes such as DNA methylation or histone modifications are mechanisms that affect gene transcription (10) . Accumulating evidence suggests the role for epigenetic dysregulation in the initiation and progression of cancer (11) , including PDAC (12) . For example, DNA methylation is a well-known mechanism that inactivates tumor suppressor genes; aberrant CpG island hypermethylation in the p16 gene was reported in PanINs (13) and PDAC (14) . Histone modification is also a target of dysregulation in pancreatic neoplasms (12) , as shown in a recent report demonstrating the significance of certain histone modifiers for pancreatic tumor development (15, 16) .
Trimethylated lysine 27 in histone H3 (H3K27me3), a histone modification involved in the repression of numerous key developmental genes, germ line development and cell-cycle regulation (17) , is deregulated in a wide variety of cancers (18) . The H3K27 histone methyltransferase EZH2 is overexpressed in PDAC and contributes to cancer cell proliferation (19) . KDM6B, also known as JMJD3, is a histone demethylase that removes the H3K27me3 methyl marks and transcriptionally activates its target genes (20) . KDM6B is a proposed tumor suppressor gene since KDM6B is induced by oncogenic RAS in human fibroblasts and increased KDM6B activates p16/INK4a gene transcription, thus contributing to oncogene-induced senescence (OIS) (21, 22) . Recent studies revealed distinct roles of KDM6B in different cancer types; in addition to the anti-tumorigenic role via p16 induction (21, 22) , a protumor role was also proposed in prostate cancer (23) , a subset of lymphoma (24) , breast cancer (25) and renal cell carcinoma (26) . Since histone demethylases exert their activity in a cell type-specific manner (27) , the role for KDM6B in PDAC remains to be elucidated.
KDM6B expression is downregulated in various human cancers (21, 22) , whereas KDM6B expression in pancreatic neoplasia remains unknown. The KDM6B gene is located on the short arm of chromosome 17 (17p13.1), close to the p53 tumor suppressor gene (21, 22, 28) . As allele losses at 17p13 are one of the most frequent genetic lesions in human cancer (29) , loss of heterozygosity (LOH) at 17p13.1 supposedly contributes to the downregulation of KDM6B expression in cancer (21, 22, 28) . In an earlier study, using single nucleotide polymorphism arrays, we identified LOH at 17p in 21 of 25 (84%) pancreatic cancer cell lines (30) .
In this report, we aimed to resolve the role of KDM6B in pancreatic tumor development. Consistent with the fact that oncogenic KRAS mutations are detected in nearly all premalignant pancreatic lesions (3), we found that KDM6B, which is located downstream of KRAS, was upregulated in low-grade PanINs. Remarkably, KDM6B expression decreased through the malignant progression, with the lowest expression level in poorly differentiated PDAC. We also identified the CCAAT-enhancer binding protein alpha (CEBPA) gene downstream of KDM6B and showed that the expression profiles of these two genes were well-correlated in human PDAC tumors. We demonstrated that attenuation of the KDM6B-C/EBPα axis exacerbates neoplastic progression in the pancreas.
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Materials and methods
Immunohistochemical analysis of human pancreas tissue
For the evaluation of normal pancreatic ducts and PanIN lesions, surgically resected pancreata harboring invasive ductal adenocarcinoma were used for immunohistochemical analysis. The pancreata were obtained from patients who underwent pancreatectomy for PDAC at the University of Tokyo between April 2012 and January 2013. These procedures were approved by the Ethical Committee for Clinical Research of our institution, and written informed consent was obtained from each patient. Multiple hematoxylin and eosin stained paraffin sections of routinely examined pancreatic tissue surrounding PDAC were screened by light microscopy for duct lesions. Each duct lesion was classified as PanIN-1, PanIN-2 or PanIN-3 according to previously described criteria (4) . In 10 sections retrieved from 7 patients, 184 duct lesions were identified (100 PanIN-1, 49 PanIN-2 and 35 PanIN-3). Also, 95 normal pancreatic ducts (adjacent to PDAC) were analyzed. Patients characteristics are described in Supplementary Table S1 , available at Carcinogenesis Online.
For the evaluation of PDAC, we also used commercially available tissue microarrays containing human PDAC (PA805, US Biomax). Cores with insufficient tissue were unsuitable for evaluation and were excluded from the analysis; the remaining 47 cores with PDAC (11 well-differentiated, 24 moderately differentiated and 12 poorly differentiated ductal adenocarcinoma specimens) were analyzed. A list of samples analyzed is shown in Supplementary Table  S2 , available at Carcinogenesis Online.
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue specimens using citrate-microwave antigen retrieval. Rabbit polyclonal anti-KDM6B antibody (ab38113, 5 μg/ml), mouse monoclonal anti-CDKN2A/p16INK4a antibody (ab54210, 1:200 dilution) and rabbit polyclonal anti-C/EBPα antibody (CST2295, Cell Signaling Technology; 1:50 dilution) were used. After incubation with biotinylated secondary antibodies and avidin-biotin-peroxidase (VECTASTAIN Elite ABC kit, Vector Laboratories), reactions were developed using diaminobenzidine as chromogenic substrate. Subsequently, the slides were briefly counterstained with hematoxylin. For the negative control, primary antibodies were omitted.
KDM6B and C/EBPα protein expression was quantified by the proportions of positive cells and staining intensity, as described previously (26, 31) with slight modification. Briefly, proportions of KDM6B or C/EBPα positive cells within a duct lesion or a PDAC core on tissue microarrays were scored as follows: 0, <5% positive cells; 1, 5-50% positive cells; 2, >50% positive cells. Staining intensity was scored as follows: 0, no staining; 1, faint staining; 2, moderate staining; 3, dark staining. Based on the sum of proportional scores and intensity scores (staining scores), a lesion was classified as follows: negative, when the combined score was 0 or 1; weak, when the combined score was 2 or 3; strong, when the combined score was 4 or 5. Two of the authors (K.Y. and K.T.) separately evaluated the immunohistochemical labeling in each case, and there was no disagreement.
Cell culture
BxPC3, PANC1 and SU.86.86 cells were purchased from the American Type Culture Collection (Manassas, VA). MiaPaCa2 cells were obtained from the Japanese Collection of Research Bioresources (Osaka, Japan). BxPC3 and SU.86.86 cells were cultured in RPMI1640 (Sigma) media supplemented with 10% fetal bovine serum (Invitrogen). All the other cell lines were maintained in Dulbecco's modified eagle medium (DMEM; Sigma) supplemented with 10% fetal bovine serum.
Short hairpin RNAs
Knockdown experiments were performed as described previously (32) using pLKO.1-puro-based lentiviruses expressing specific short hairpin RNAs (shRNAs) following the manufacturer's instruction (Addgene). We infected indicated cells with lentiviruses expressing shRNAs in the presence of 8 μg/ml polybrene. After 24 h, stably transfected cells were selected with puromycin (4 μg/ml). The day of infection was considered day 0, and all in vitro assays were carried out as described. A scramble shRNA, used as a negative control, and shRNAs against CEBPA were purchased from Open Biosystems. Two shRNAs against KDM6B, KDM6B-KD_3 and KDM6B-KD_4 were cited from two previous reports (21, 22) , respectively. The targeted sequences for the shRNAs were as follows: KDM6B-KD_1, 5′-CCTCGTCATCTCAGTTCTCTA-3′; KDM6B-KD_2, 5′-GCGATGTGGAGGTGTTTAACA-3′; KDM6B-KD_3, 5′-GA TGATCTC TATGCATCCA-3′; KDM6B-KD_4, 5′-CAGCAG GAATG CCAA GGTGAA-3′; CEBPA-KD_1, 5′-GCAACTCTAGTATTTAGGATA-3′; CEBPA-KD_2, 5′-GCTGGAGCTGACCAGTGACAA-3′; CEBPA-KD_3, 5′-GCAC GAGACGTCCATCGACAT-3′.
Orthotopic implantation and intrasplenic injection of tumor cells
All animal experiments were reviewed and approved by the Animal Ethics Committee of the University of Tokyo. Nude mice were purchased from CLEA Japan. For all in vivo studies, BxPC3 or SU86.86 cells were used at day 10 after lentiviral knockdown. Orthotopic implantation of cancer cells was performed as follows. Briefly, 7-week-old male nude mice were anesthetized by intraperitoneal injection of pentobarbital sodium (5 mg/g), followed by a left lateral laparotomy. Cancer cells (1.5 × 10 6 ) suspended in 50 μl of ice-cold phosphate-buffered saline were injected into the tail of the pancreas with a 30 gauge needle, and the incision was sutured with staplers. Mice were killed 7 weeks after transplantation, and tumor progression was examined. Peritoneal dissemination and liver metastasis were further confirmed by histological examination. Histology was evaluated by hematoxylin and eosin staining. For experiments using SU.86.86 cell lines, the body weight of mice at sacrifice and weight of enucleated tumors were also examined. For intrasplenic injection, 1 × 10 6 cells suspended in 50 μl of ice-cold phosphate-buffered saline were injected into the spleen, and the mice were monitored for survival. and plated over 1.5 ml of bottom agar (0.8% Bacto agar and DMEM) in a 35 mm dish. After 21 day of culture, the number of colonies was counted in five random high-power fields (magnitude of ×200) per dish, and the total number of colonies from five fields is shown as the result.
Soft agar colony formation assay
Tumor sphere formation assay
For the sphere formation assay, cells were used at day 8 after lentiviral knockdown of KDM6B or CEBPA. Tumor sphere culture was performed as described previously (33) . Briefly, cells were cultured in suspension in DMEM (Sigma) supplemented with 2% B27 (Invitrogen), 20 ng/ml epidermal growth factor (Wako), 10 ng/ml basic fibroblasts growth factor (Invitrogen) and 1% methylcellulose (Sigma). Five hundred cells were plated into 24 well Ultra Low Attachment plates (Costar), and spheres with a diameter larger than 70 μm were counted after 10 day of culture.
Quantitative real-time PCR Detailed methods are described in Supplementary Materials and Methods, available at Carcinogenesis Online. 
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Microarray analysis
Total RNA was extracted from BxPC3 cells at day 10 after lentiviral transfection with Ctrl or KDM6B-KD_1 shRNAs. Cy3-labeled cRNAs were prepared using the Quick Amp Labelling Kit and hybridized to Whole Human Genome Microarrays (4 × 44 K, G4110F) according to the manufacturer's instructions (Agilent Technologies). Data were normalized by the normalization method, using the statistical software R and the Bioconductor package 'Agi4x44PreProcess' (Pedro Lopez-Romero). To compare microarray gene expression data from Ctrl and KDM6B-KD_1 BxPC3 cells, gene set enrichment analysis (34) was performed. The gene set was obtained from the Molecular Signatures Database. Statistical significance was determined by the cut-off line value of normalized P < 0.05 and false discovery rate q < 0.30. Probe design files and microarray data have been submitted to the National Center for Biotechnology Information Gene Expression Omnibus database under accession number GSE28155.
Immunoblotting
Immunoblotting of the cell lysates was performed as described previously (32) using primary antibodies against C/EBPα (1:300, ab74404, Abcam), β-actin (1:10 000, Sigma-Aldrich), H3K27me3 (1:1000, ab6002, Abcam) and histone H3 (1:20 000, ab1791, Abcam). A horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences) was used at 1:5000 dilution. Proteinantibody complexes were detected using ECL Plus (Amersham Biosciences).
As the positive control for C/EBPα, whole-cell lysate was prepared from 293T cells that were transfected with pcDNA3-HA-Cebpa.
Chromatin immunoprecipitation analysis
Detailed methods are described in Supplementary Materials and Methods, available at Carcinogenesis Online.
EHZ2 inhibitor
Cells were treated with GSK126, an EZH2 inhibitor (Active Biochemicals), at indicated doses for 72 h and were harvested for further analyses.
Statistical analysis
All the numerical values were expressed as the mean ± SEM of at least three independent experiments. Statistical significance was determined by Student's t-test, χ 2 test, or Fisher's exact test. P < 0.05 was considered significant.
Results
KDM6B was expressed in a majority of low-grade PanINs, but the rate was decreased through the progression of pancreatic neoplasms
We analyzed the expression status of KDM6B protein in the human pancreatic tissues using patient-derived pancreata and a commercially available tissue microarray containing PDAC tumors of various pathological grades (Figure 1 and Supplementary Table S1 Figure 1A and B). These results raised the possibility that loss of KDM6B expression might be linked to the development of pancreatic neoplasms. CDKN2A, which encodes the p16 protein, is a tumor suppressor gene that is frequently lost during the malignant transformation from PanIN to PDAC (2, 9) . CDKN2A also contributes to OIS downstream of KDM6B (21, 22) . Consistently, most of the early PanIN lesions with positive KDM6B expression also showed positive staining for p16 ( Figure 1A[b,c] ). However, it is noteworthy that the expression of KDM6B and p16 did not correspond in some high-grade PanINs and PDAC lesions ( Figure 1A[d,f] ), leading us to hypothesize that KDM6B might target genes other than CDKN2A through PDAC progression.
KDM6B depletion enhanced tumorigenesis of PDAC cells both in vitro and in vivo
To address whether KDM6B has any role in PDAC other than p16 induction, we stably knocked down KDM6B expression in PDAC cell lines with homozygous deletion of the p16/CDKN2A locus (BxPC3, SU.86.86, PANC1, MiaPaCa2) (35) and assessed their phenotypic change by both in vitro and in vivo analyses. Based on quantitative real-time PCR and immunoblot data, the shRNAs KDM6B-KD_1 and KDM6B-KD _2 were the most efficient among the four constructs tested (Supplementary Figure S1A and B, available at Carcinogenesis Online) and were therefore chosen for subsequent studies.
When BxPC3 cells stably expressing shRNAs (KDM6B-KD) or Ctrl shRNA were orthotopically implanted into the pancreas of nude mice, mice injected with KDM6B-KD BxPC3 cells developed peritoneal dissemination more frequently than mice transplanted with Ctrl cells [Ctrl, 9.5% (2/21); KDM6B-KD_1, 45.5% (5/11); KDM6B-KD_2, 100% (8/8); Figure 2A , left], indicating that loss of KDM6B affects the malignant properties of PDAC cells in a p16-independent mechanism. Consistently, when these cells were xenotransplanted into the spleen of nude mice, their survival rates were reduced significantly (n = 6 for each group; log-rank test; P = 0.029; Figure 2B ). To rule out any cell line-specific effects, we also implanted the KDM6B-KD_1 SU.86.86 cells into the pancreas, and the resulting tumors showed a significant increase in peritoneal dissemination (13% versus 71%, P = 0.020) and in liver metastases (38% versus 86%, P = 0.057; Figure 2A , right). In addition, we observed a significant loss of body weight (27.4 g versus 21.6 g, P = 5.8 × 10 −4 ) and increased tumor weight (1.1 g versus 2.7 g, P = 6.6 × 10 −5 ) in mice injected with the KDM6B-KD_1 SU.86.86 cells ( Figure 2C and Supplementary Figure  S1C , available at Carcinogenesis Online). Consistent with these in vivo data, KDM6B-KD_1 and KDM6B-KD_2 cells also showed significant increases in anchorage-independent growth ( Figure 2D and Supplementary Figure S1D , available at Carcinogenesis Online) and tumor sphere-forming capacity, an indicator of in vivo tumor-initiating potential (33) (Figure 2E and Supplementary Figure S1E , available at Carcinogenesis Online). Collectively, our data suggest that loss of KDM6B enhanced tumorigenicity in PDAC cells.
To examine if the tumorigenic effect of decreased KDM6B could be affected by intact p16, we forced the expression of the p16 gene in the KDM6B-KD_1 cells. As a result, in the p16-expressing KDM6B-KD_1 BxPC3 cells, growth was arrested, and the cells could not be used for further experiments (Supplementary Figure S1F and G, available at Carcinogenesis Online). These data suggest that the tumorigenic effect by KDM6B knockdown in PDAC is mediated by other factors but requires loss of p16 as a preconditioning factor.
A tumor suppressor gene CEBPA was identified as a downstream target of KDM6B
To identify genes responsible for acquired enhanced tumorigenicity in KDM6B-KD cells, we compared the gene expression profiles of KDM6B-KD_1 and Ctrl cells. Using 2-fold change as a cut-off and a P value of 0.05, 1545 genes were differentially expressed in KDM6B-KD_1 cells; 906 (2.2%) genes were upregulated, whereas 639 genes (1.56%) were downregulated. To unravel the transcriptional module regulated by KDM6B, we performed gene set enrichment analysis (34) using the gene sets that predict transcription factors and transcription factor binding sites. Among the 615 gene sets examined, the genes with C/EBPα binding sites were significantly enriched in KDM6B-KD cells ( Figure 3A , left and Table I ). Also, CCAAT/enhancer-binding protein target gene set (36) showed a high enrichment score in gene set enrichment analysis ( Figure 3A, right) . Downregulated CEBPA messenger RNA (mRNA) expression and reduced C/EBPα protein were confirmed in KDM6B -KD cells ( Figure 3B and C, Supplementary Figure S2A and B, available at Carcinogenesis Online). The downregulation of CEBPA after KDM6B knockdown was also demonstrated in a variety of cancer cell lines (Supplementary Figure S2C , available at Carcinogenesis Online).
As these data suggest that CEBPA expression is regulated by KDM6B, we next examined the association of KDM6B at the CEBPA promoter. A chromatin immunoprecipitation assay revealed an enrichment of KDM6B at the region upstream of CEBPA transcription start site, which was decreased upon KDM6B knockdown ( Figure 3D and E and Supplementary Figure S3A and B, available at Carcinogenesis Online). We also determined if CEBPA expression is repressed depending of polycomb repressive complex 2 (PRC2) through its H3K27 methylation activity. A chromatin immunoprecipitation assay showed increased levels of H3K27me3 ( Figure 3F and H and Supplementary Figure S3C , available at Carcinogenesis Online) and SUZ12, a component of PRC2, and occupancy at the upstream region of the CEBPA transcription start site, along with CEBPA downregulation following KDM6B knockdown ( Figure 3G and Supplementary Figure S3D , available at Carcinogenesis Online).
To further confirm the involvement of PRC2-mediated repression, we next tested pharmacological inhibition of EZH2, a catalytic subunit of the PRC2. As expected, treatment of PDAC cells with GSK126, a highly specific small molecule inhibitor of EZH2 methyltransferase activity (37) , increased CEBPA mRNA expression along with global reduction of H3K27me3 levels ( Figure 3I and J) . Interestingly, the restoration of CEBPA mRNA expression by GSK126 treatment was significantly impaired in KDM6B-KD cells, suggesting that loss of H3K27me3 at the global level by EZH2 inhibition is not sufficient, but demethylation of H3K27me3 at specific regions by KDM6B is required to activate CEBPA mRNA expression. To rule out the possibility that the KDM6B knockdown upregulated the expression of PRC2 components and then abrogated the inhibitory effect of GSK126, we examined the protein levels of SUZ12, EZH2 and EED, which are PRC2 components. No obvious increase in the level of these PRC2 components was observed in any KDM6B-KD cells compared with Ctrl cells (Supplementary Figure S3F , available at Carcinogenesis Online). Besides, KDM6B depletion did not increase the global level of H3K27me3 in the two established KDM6B-KD cell lines (Supplementary Figure S3G , available at Carcinogenesis Online) though KDM6B is a histone demethylase catalyzing H3K27me3. Taken together, these results excluded the possibility that KDM6B knockdown attenuated the effect of GSK126 by increasing PRC2 activity.
To confirm the pharmacological data, we performed knockdown experiments using small interfering RNA against EZH2. Small interfering RNA-mediated EZH2 knockdown increased CEBPA expression in Ctrl cells, and the effect was attenuated in KDM6B-KD cells ( Figure 3K and L and Supplementary Figure S4G and H, available at Carcinogenesis Online). These data are consistent with those from GSK126 experiments.
CEBPA was responsible for the enhanced tumorigenesis of PDAC cells after KDM6B ablation C/EBPα is downregulated in a variety of solid tumors; thus, it is considered a tumor suppressor gene (38) . Therefore, to determine if CEBPA downregulation is responsible for the enhanced tumorigenesis of KDM6B-KD PDAC cells, we knocked down CEBPA expression in PDAC cells. Among the three shRNAs tested, CEBPA-KD_1 and CEBPA-KD_3 were more efficient and were used in subsequent studies (Supplementary Figure S4A and B, available at Carcinogenesis Online). In vitro analyses showed that CEBPA knockdown resulted in increased soft agar colony formation ( Figure 4A ) and increased sphere formation ( Figure 4B ). When CEBPA-KD_3 cells were orthotopically implanted into the pancreas of nude mice, all mice developed peritoneal dissemination (8/8, Figure 4C , see also Figure 2A ). Collectively, CEBPA-KD PDAC cells recapitulated the phenotypes of the KDM6B-KD PDAC cells.
When C/EBPα was ectopically expressed in KDM6B-KD_1 BxPC3 cells (Figure 4D ), the enhanced sphere-forming ability caused by KDM6B knockdown was rescued ( Figure 4E ), whereas rates of cell growth, apoptosis and cell cycle under conventional culture conditions were not affected (Supplementary Figure S4C -F, available at Carcinogenesis Online). To further validate the anti-tumorigenic role of C/EBPα, we next restored CEBPA expression in PDAC cells and evaluated sphere-forming capacity. For this purpose, PANC1 cells, a cell line with high sphere-forming capacity, were treated with EZH2 inhibitor GSK126. In Ctrl PANC1 cells, GSK126 treatment reduced global H3K27me3 levels, increased CEBPA expression (Supplementary Figure 4G and H, available at Carcinogenesis Online. See also Figure 3I and J) and suppressed tumor sphere formation in a dose-dependent manner ( Figure 4F) . Notably, however, this inhibitory effect of GSK126 on tumor sphere formation was impaired in KDM6B-KD_1 cells, where CEBPA expression was not restored (Supplementary Figure 4H , available at Carcinogenesis Online). Notably, GSK126 had no significant effect on proliferation rates under adherent conditions in the doses tested (data not shown). All these results indicate the negative impact of C/EBPα expression on tumorigenic properties of PDAC cells. Microarray data comparing Ctrl and KDM6B-KD_1 BxPC3 cells were analyzed by gene set enrichment analysis using transcription factor target sets containing 615 gene sets. Each gene set contains genes that share biding sites for an indicated transcription factor. Statistical significance was determined by the cut-off line value of normalized (NOM) P < 0.05 and false discovery rate (FDR) q < 0.30. Gene sets are sorted and ranked based on normalized enrichment score (NES). ES, enrichment score. 
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KDM6B and C/EBPα expression patterns were correlated in human PDAC tissues
Finally, to emphasize the functional relevance between KDM6B and C/EBPα in human PDAC, we performed an immunohistochemical analysis of C/EBPα using the same serial sections examined for KDM6B expression in Figure 1 . The pattern of C/EBPα immunoreactivity in the serial sections was comparable with that of KDM6B ( Figure 5A ); C/EBPα expression was most predominantly observed in PanINs (88.5%, 169/191), followed by PDAC (74.5%, 35/47) and normal pancreatic ducts (32.6%, 29/89; Figure 5B ). Strong C/ EBPα expression was observed most frequently in PanINs (62.8%, 120/191), followed by PDACs (34.0%, 16/47) and normal pancreatic ducts (6.7%, 6/89; Figure 5B ). In addition, the positive correlation between KDM6B and C/EBPα expression was statistically confirmed in 47 PDAC tumor specimens contained in tissue microarrays (Fisher's exact test, P < 0.0001; Figure 5C and Supplementary Table S2, available at Carcinogenesis Online). Interestingly, C/EBPα expression declined in the moderate to poorly differentiated PDAC tumors ( Figure 5A and B) , revealing the same tendency as that of KDM6B, which substantiates a role for a KDM6B-C/EBPα axis in PDAC cells.
Discussion
In this study, we demonstrated a novel role for KDM6B in PDAC cells. It is noteworthy that KDM6B knockdown in PDAC cell lines uniformly resulted in enhanced tumorigenesis regardless of KRAS mutations; BxPC3 harbors wild-type KRAS, whereas other PDAC cell lines harbor mutated KRAS. Moreover, all the cell lines used in this study retain homozygous deletion of p16/CDKN2a (35) . These findings indicated that KDM6B plays a role distinct from the KRAS-KDM6B-p16-mediated induction of OIS (21, 22) . Of course, we cannot exclude the possibility that the loss of KDM6B functionally cooperates with the KRAS-GTP activity; however, our data corroborate the notion that epigenetic regulation in cancer phenotypes does not always require genetic mutations (39) .
KDM6B was highly expressed in low-grade PanINs, in contrast to very low expression level in normal ducts. It is likely that coexpression of p16 and KDM6B in PanIN-1 lesions reflects active oncogeneinduced senescence (40) mediated by the RAS-KDM6B-p16 axis (21, 22) . Meanwhile, we also found that KDM6B is expressed in several high-grade PanIN lesions and PDAC tumors, where p16 expression is already lost, which caused us to explore a p16-independent role for KDM6B in advanced pancreatic neoplasms. Consequently, we identified functional interaction between KDM6B and C/EBPα. We also revealed a significant role for the KDM6B-C/EBPα axis in the tumorigenicity of PDAC cells.
Although a recent report documented the upregulation of KDM6B in PDAC specimens (15) , it does not contradict our findings because the upregulation was compared with normal ducts, where KDM6B was rarely expressed in normal ducts in our study. Notably, malignancy-related mechanisms, including LOH, may lead to the reduction of KDM6B expression in PDAC cells, where the tumor-suppressive OIS has been disabled. Actually, KDM6B expression was suppressed by histone deacetylation in a group of PDAC cell lines in our analysis (data not shown). Also, a recent study reported that missense mutations and aberrant methylation of the KDM6B gene was detected in glioblastoma, resulting in a block to terminal differentiation of glioblastoma stem cells (41) . Thus, understanding the mechanisms underlying the suppression of KDM6B in PDAC may provide a clue to regulate the malignant features of PDAC cells.
Previous studies showed that C/EBPα negatively regulates the selfrenewal capacity of hematopoietic stem cells (42, 43) , whereas CEBPA expression is reduced in leukemia-initiating cells (44) and in a variety of cancers (38) , where forced expression of CEBPA impairs the proliferation and tumorigenicity of cancer cells (45) . These results agree with our findings that suppression of C/EBPα leads to enhanced tumorigenicity of PDAC cells. Notably, however, KDM6B knockdown in other cancer types, such as lung and colon cancer cells, did not lead to similar effects on tumorigenesis (data not shown), whereas CEBPA downregulation was observed in all the cell lines. Remarkably, C/EBPα promotes cell growth in some malignancy including prostate cancer and hepatocellular carcinoma (46, 47) . These findings suggest a cell typespecific role for KDM6B and C/EBPα and the existence of salvage mechanisms from tumorigenesis caused by loss of KDM6B-C/EBPα in other types of cancer. Accordingly, interfering with the molecular pathway caused by KDM6B-C/EBPα abrogation in PDAC tumors may be clinically effective. Additionally, the salvage pathway could be significant against loss of KDM6B-C/EBPα in other types of cancer.
Dysregulation of CEBPA expression is widely reported in human cancer, for which various mechanisms have been described (38) . DNA methylation is the most well-documented mechanism in solid tumors (31, 48, 49) , including pancreatic cancer (50) . Although some analyses are still required to resolve the detailed mechanism, we propose a possible regulation mechanism whereby CEBPA transcription is epigenetically regulated in a H3K27-dependent manner without DNA methylation. In fact, during the course of CEBPA downregulation after KDM6B knockdown, bisulfite sequencing did not reveal any change in the DNA methylation profile in the upstream promoter region of CEBPA (data not shown). Our findings emphasize the significance of altered histone modification in the regulation of tumor suppressor genes in cancer cells.
As KDM6B activates its target genes by demethylating H3K27me3 and counterbalancing PRC2-mediated silencing, we expected that EZH2 inhibition would rescue the phenotype of KDM6B-depleted PDAC cells. However, though pharmacological inhibition of EZH2 by GSK126 increased CEBPA expression in PDAC cells, this effect was impaired by KDM6B ablation, suggesting that reactivation of CEBPA expression after EZH2 inhibitor treatment was dependent on KDM6B activity. This result is consistent with the previous report that pharmacological inhibition of EZH2 activity by GSK126 was not sufficient for complete reactivation of several PRC2-silenced genes, where the requirement for additional chromatin factors was proposed (37) . Our results suggest the possibility that the genetic status of KDM6B, including LOH or mutations, might be an important factor affecting the cellular sensitivity to GSK126, which has received much attention as a therapy for a broad range of malignancies with EZH2-activating mutations or EZH2 overexpression. Taken together, our data highlight the crucial role of KDM6B in the transcriptional regulation of a tumor suppressor gene CEBPA in PDAC, and our data demonstrate the importance of clarifying how KDM6B expression is regulated and of restoring KDM6B expression in cancer. Currently, some low molecular weight compounds targeting various histone methyltransferases, including EZH2, are being developed and applied to clinical trials. Consequently, it is of broad interest to unravel whether the status of active histone demethylating enzymes is an important factor in the therapeutic strategy using methyltransferase inhibitors.
